How does a scientist get credit in the RPES if a substantial portion of the assignment involves a CRADA with a confidentiality agreement which prevents publication of the research?
The concern about inability to publish is misplaced, since RPES evaluates impact, stature, and recognition… not the publication record. If the scientist is involved in a confidential CRADA, then by definition a firm has found the technology useful and/or a significant improvement, and has invested or plans to invest in the technology. The accomplishment statement must describe the nature of the improvement and extent of investment, and be supported by a statement from an official of the firm. That official should also be listed as an IDR contact on the ARS-570. The bottom line is that panels cannot credit “potential impact,” and cannot credit any impact that is not properly documented. 7. The continued emphasis on senior authorship is of concern in team research and graduate student/major professor situations. Younger colleagues are often given senior authorship to permit them to advance, even when a mentor provides funds and many of the ideas, and does a lot of work on the manuscrip
